Dongwha Pharm.Co.,Ltd (000020.KS)
KRW 6360.0
(-1.7%)
KRW 6360.0
(-1.7%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 564.97 Billion KRW | 22.52% |
| 2022 | 461.13 Billion KRW | 2.98% |
| 2021 | 447.8 Billion KRW | 3.23% |
| 2020 | 433.8 Billion KRW | 15.37% |
| 2019 | 376.02 Billion KRW | 1.47% |
| 2018 | 370.59 Billion KRW | 0.92% |
| 2017 | 367.22 Billion KRW | 13.13% |
| 2016 | 324.6 Billion KRW | 2.34% |
| 2015 | 317.18 Billion KRW | 1.31% |
| 2014 | 313.07 Billion KRW | -0.98% |
| 2013 | 316.16 Billion KRW | -2.5% |
| 2012 | 324.28 Billion KRW | -4.46% |
| 2011 | 339.43 Billion KRW | 4.76% |
| 2010 | 324 Billion KRW | 4.86% |
| 2009 | 308.99 Billion KRW | -0.8% |
| 2008 | 311.47 Billion KRW | 41.31% |
| 2007 | 220.42 Billion KRW | 11.35% |
| 2006 | 197.94 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 558.7 Billion KRW | 0.1% |
| 2024 Q1 | 558.12 Billion KRW | -1.21% |
| 2023 Q3 | 490.15 Billion KRW | 1.74% |
| 2023 Q4 | 564.97 Billion KRW | 15.26% |
| 2023 Q1 | 476.99 Billion KRW | 3.44% |
| 2023 Q2 | 481.75 Billion KRW | 1.0% |
| 2023 FY | 564.97 Billion KRW | 22.52% |
| 2022 Q3 | 468.46 Billion KRW | 0.98% |
| 2022 Q4 | 461.13 Billion KRW | -1.56% |
| 2022 FY | 461.13 Billion KRW | 2.98% |
| 2022 Q2 | 463.91 Billion KRW | 0.86% |
| 2022 Q1 | 459.96 Billion KRW | 2.72% |
| 2021 Q4 | 447.8 Billion KRW | -0.02% |
| 2021 Q2 | 447.07 Billion KRW | 2.24% |
| 2021 FY | 447.8 Billion KRW | 3.23% |
| 2021 Q3 | 447.87 Billion KRW | 0.18% |
| 2021 Q1 | 437.26 Billion KRW | 0.8% |
| 2020 Q3 | 424.56 Billion KRW | 9.34% |
| 2020 FY | 433.8 Billion KRW | 15.37% |
| 2020 Q1 | 376.18 Billion KRW | 0.04% |
| 2020 Q2 | 388.29 Billion KRW | 3.22% |
| 2020 Q4 | 433.8 Billion KRW | 2.18% |
| 2019 Q4 | 376.02 Billion KRW | 0.33% |
| 2019 FY | 376.02 Billion KRW | 1.47% |
| 2019 Q3 | 374.77 Billion KRW | -0.34% |
| 2019 Q2 | 376.07 Billion KRW | 1.02% |
| 2019 Q1 | 372.27 Billion KRW | 0.45% |
| 2018 Q3 | 372.53 Billion KRW | -0.64% |
| 2018 Q2 | 374.92 Billion KRW | -1.51% |
| 2018 Q1 | 380.67 Billion KRW | 3.66% |
| 2018 FY | 370.59 Billion KRW | 0.92% |
| 2018 Q4 | 370.59 Billion KRW | -0.52% |
| 2017 Q4 | 367.22 Billion KRW | 8.35% |
| 2017 Q3 | 338.91 Billion KRW | 1.92% |
| 2017 Q1 | 322.49 Billion KRW | -0.65% |
| 2017 FY | 367.22 Billion KRW | 13.13% |
| 2017 Q2 | 332.51 Billion KRW | 3.11% |
| 2016 FY | 324.6 Billion KRW | 2.34% |
| 2016 Q2 | 330.91 Billion KRW | 2.05% |
| 2016 Q3 | 328.42 Billion KRW | -0.75% |
| 2016 Q4 | 324.6 Billion KRW | -1.16% |
| 2016 Q1 | 324.27 Billion KRW | 2.24% |
| 2015 Q4 | 317.18 Billion KRW | -0.62% |
| 2015 Q3 | 319.18 Billion KRW | -0.28% |
| 2015 Q2 | 320.09 Billion KRW | 0.84% |
| 2015 Q1 | 317.42 Billion KRW | 1.39% |
| 2015 FY | 317.18 Billion KRW | 1.31% |
| 2014 Q1 | 316.96 Billion KRW | 0.25% |
| 2014 FY | 313.07 Billion KRW | -0.98% |
| 2014 Q4 | 313.07 Billion KRW | -2.46% |
| 2014 Q3 | 320.98 Billion KRW | 0.2% |
| 2014 Q2 | 320.34 Billion KRW | 1.07% |
| 2013 Q4 | 316.16 Billion KRW | -1.39% |
| 2013 FY | 316.16 Billion KRW | -2.5% |
| 2013 Q1 | 339.39 Billion KRW | 4.66% |
| 2013 Q2 | 329.07 Billion KRW | -3.04% |
| 2013 Q3 | 320.63 Billion KRW | -2.57% |
| 2012 Q2 | 343.9 Billion KRW | 0.45% |
| 2012 Q1 | 342.36 Billion KRW | 0.86% |
| 2012 Q4 | 324.28 Billion KRW | -3.59% |
| 2012 FY | 324.28 Billion KRW | -4.46% |
| 2012 Q3 | 336.37 Billion KRW | -2.19% |
| 2011 Q4 | 339.43 Billion KRW | 1.15% |
| 2011 Q1 | 335.94 Billion KRW | 3.68% |
| 2011 FY | 339.43 Billion KRW | 4.76% |
| 2011 Q3 | 335.56 Billion KRW | -2.51% |
| 2011 Q2 | 344.2 Billion KRW | 2.46% |
| 2010 Q3 | 320.39 Billion KRW | -0.04% |
| 2010 FY | 324 Billion KRW | 4.86% |
| 2010 Q4 | 324 Billion KRW | 1.13% |
| 2010 Q1 | 319.47 Billion KRW | 0.0% |
| 2010 Q2 | 320.52 Billion KRW | 0.33% |
| 2009 Q2 | 315.09 Billion KRW | 1.16% |
| 2009 Q1 | 311.47 Billion KRW | -1.46% |
| 2009 FY | 308.99 Billion KRW | -0.8% |
| 2009 Q3 | 306.91 Billion KRW | -2.6% |
| 2008 Q4 | 316.09 Billion KRW | 22.91% |
| 2008 Q1 | 220.42 Billion KRW | -0.93% |
| 2008 Q2 | 229.64 Billion KRW | 4.18% |
| 2008 FY | 311.47 Billion KRW | 41.31% |
| 2008 Q3 | 257.18 Billion KRW | 11.99% |
| 2007 FY | 220.42 Billion KRW | 11.35% |
| 2007 Q2 | 201.1 Billion KRW | 0.0% |
| 2007 Q3 | 206.72 Billion KRW | 2.79% |
| 2007 Q4 | 222.49 Billion KRW | 7.63% |
| 2006 FY | 197.94 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -185.032% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 71.132% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 35.579% |
| HANDOK Inc. | 790.33 Billion KRW | 28.515% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -231.129% |
| Yuhan Corporation | 2814.07 Billion KRW | 79.923% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 57.044% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -504.384% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 71.057% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -135.654% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -20.488% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -391.395% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -138.84% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | -62.168% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -185.032% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | -34.777% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | -13.045% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | 4.144% |
| JW Holdings Corporation | 1176.26 Billion KRW | 51.969% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | 7.573% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 59.715% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 12.413% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -61.382% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -266.767% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | -52.415% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | -15.933% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -185.032% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 47.594% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 68.086% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 12.413% |
| Yuhan Corporation | 2814.07 Billion KRW | 79.923% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 35.798% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -149.325% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 43.147% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 12.413% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | -34.549% |
| Korea United Pharm Inc. | 468.86 Billion KRW | -20.499% |
| CKD Bio Corp. | 293.78 Billion KRW | -92.308% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | -11.215% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | -40.811% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -61.382% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 61.197% |
| Boryung Corporation | 922.36 Billion KRW | 38.747% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | -27.688% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -20.488% |
| JW Lifescience Corporation | 255.83 Billion KRW | -120.833% |